Aeterna Zentaris Inc.
For more information, click here: http://zlk.9nl.com/aeterna-zentaris.
The complaint alleges that Aeterna Zentaris made false and/or misleading statements or failed to disclose that: (a) the planned analysis of the Company's macimorelin clinical trial failed to meet its primary efficacy endpoint; (b) insufficient data existed to confirm that the patients in the clinical trial were accurately diagnosed with Adult Growth Hormone Deficiency; (c) a serious cardiac event could have been attributed to macimorelin; and (d) as a result, the FDA would not approve the New Drug Application for macimorelin in its present form.
On November 6, 2014, the Company revealed that the FDA would not approve the macimorelin New Drug Application in its present form.
If you suffered a loss in Aeterna Zentaris you have until January 12, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/aeterna-zentaris.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits and have helped shareholders recover millions of dollars in losses over the years. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
Für weitere Informationen, klicken Sie bitte hier: http://zlk.9nl.com/aeterna-zentaris.
Die Klage behauptet, dass Aeterna Zentaris hat falsche und / oder irreführende Angaben oder versäumt, dass Angaben zu machen: (a) die geplante Analyse der klinischen Studie macimorelin der Gesellschaft gegen ihre primäre Wirksamkeitsendpunkt zu erfüllen; (b) keine ausreichenden Daten vorhanden, um zu bestätigen, dass die Patienten in der klinischen Studie wurden exakt mit Erwachsene Wachstumshormon-Mangel diagnostiziert; (c) eine schwere Herzereignis könnte zugeschrieben haben, macimorelin; und (d) als Folge, die FDA nicht die New Drug Application genehmigen für macimorelin in seiner jetzigen Form.
Am 6. November 2014 das Unternehmen ergab, dass die FDA nicht die macimorelin New Drug Application in der vorliegenden Form zustimmen.
Wenn Sie einen Verlust in Aeterna Zentaris gelitten haben, bis 12. Januar 2015 zu beantragen, dass der Gerichtshof zu ernennen Sie als Hauptkläger. Ihre Fähigkeit, sich in einer Erholung Aktie nicht erforderlich, dass Sie sich als Hauptkläger zu dienen. Um weitere Informationen zu erhalten, wenden Sie sich Joseph E. Levi, Esq. entweder per E-Mail an jlevi@zlk.com oder telefonisch unter (212) 363-7500, Gebührenfreie Rufnummer: (877) 363-5972 oder besuchen Sie http://zlk.9nl.com/aeterna-zentaris.
Levi & Korsinskys ist ein nationales Unternehmen mit Büros in New York, New Jersey, Connecticut und Washington DC Anwälte der Kanzlei verfügen über umfangreiche Erfahrung in der Strafverfolgung Securities Litigation mit Finanzbetrug, was Investoren in der gesamten Nation in Wertpapieren und Aktionärsklagen und haben dazu beigetragen, die Aktionäre zu erholen Millionen Dollar an Verlusten im Laufe der Jahre. Für weitere Informationen, wenden Sie sich an eine der unten aufgeführten Rechtsanwälte zu kontaktieren. Attorney-Werbung. Vor Ergebnisse garantieren nicht ähnliche Ergebnisse.
tsss
US Rechtsanwälte...
Short Volume Lookup
Database Last Updated: Friday, December 12, 2014
Enter a Stock Symbol or Company Name
AEterna Zentaris Inc.
Symbol:
AEZS
Show Last Days
Date§
Hi§
Lo§
§
Total Volume
§
Short Volume
§
% Short Vol
Date Hi Lo§Total Volume Short Volume % Short Vol
§Thu, Dec 11, 2014 0.6165 0.57 323353 1500 1%
§Wed, Dec 10, 2014 0.6588 0.599 476280 19136 5%
§Tue, Dec 9, 2014 0.682 0.63 593713 24763 5%
§Mon, Dec 8, 2014 0.72 0.6495 1008726 24244 3%
§Fri, Dec 5, 2014 0.685 0.63 805328 17454 1%
§Thu, Dec 4, 2014 0.75 0.67 1183246 8028 1%
§Wed, Dec 3, 2014 0.83 0.7135 3265642 324836 10%
§Tue, Dec 2, 2014 0.79 0.674 4908510 388975 8%
§Mon, Dec 1, 2014 0.65 0.55 5015384 363273 8%
§Fri, Nov 28, 2014 0.5359 0.51 396144 22133 6%
§Thu, Nov 27, 2014 0.538 0.515 649130 Posts at 5:30pm EST 0%
§Wed, Nov 26, 2014 0.538 0.515 649130 91266 15%
§Tue, Nov 25, 2014 0.5395 0.52 611039 72783 12%
§Mon, Nov 24, 2014 0.5496 0.525 398601 34716 9%
§Fri, Nov 21, 2014 0.5496 0.52 670427 38322 6%
30 trading days available For 60 Historical Register For a Free Account
FirstPrevious12NextLast
REGSHO Guide
The Short Volume Lookup provides daily and historical REGSHO short volume data published by FINRA for stocks traded on the NYSE, NASDAQ, OTC and Pinksheet markets. Daily REGSHO is usually updated at 5:30 PM Eastern. Mighty Markets LLC., receives daily short volume from FINRA.org. No guarantees are made to the accuracy of results and no financial decisions should be based upon these results.
Table of Contents
Daily Short Volume Lookup
1. What is REGSHO
1.2 Understanding the Daily REGSHO report
1.3 What it is and is not
2. Daily REGSHO Volumes
2.1 Short
2.3 TRF Total
2.4 Exempt Short
2.5 Total
2.6 Adjusted
3. Additional Daily Data
3.1 Date
3.2 Hi/Lo
3.3 Total Dollar Volume
3.4 Number of Trades
3.5 Trading Status
3.6 CUSIP
1. What is REGSHO
Regulation SHO was introduced in the Securities Exchange Act Release No. 50103 and became effective as of on September 7, 2004 but did not become mandatory until January 3, 2005. REGSHO was adopted to provide market transparency, regulation, and specifically prevention of "Naked Short Selling". REGSHO has two specific parts, Rule 200 and Rule 203.
Rule 200 - Definitions and Marking Requirements.
This rule provides a few technical requirements for market makers and broker-dealers but has a major requirement concerning the marking of shares sold. It specifies shares sold during trading to be identified and marked as being sold "long," "short," or "short exempt."
Rule 203 - Locate and Delivery Requirements.
This rule clearly defines that broker-dealers, before making short sales in any equity securities, must locate the securities available first, before borrowing. This is in order to be able to deliver the securities on the settlement date. The second part of this rule imposes requirements on broker-dealers which have had substantial amounts of failures to deliver for securities.
1.2 Understanding the Daily REGSHO report
At the end of each trading day, a RegSHO report is submitted to FINRA by each of its Trade Reporting Facilities (TRF). A TRF, according to FINRA, "provides FINRA members with a mechanism for the reporting of transactions effected otherwise than on an exchange." More information about them can be found here. FINRA Trade Reporting Facility
Simply put, a TRF is a way to report security transactions that happen on registered national exchanges, quotation systems, or other platforms. Currently there are 3 RegSHO reports generated for the NASDAQ, NYSE, and OTC Markets and Others.
Each report lists the total amount of volume of shares traded for each identification marker, "short", "short exempt", and "long" per security.
1.3 What it is and is not
It is highly contested whether or not the daily RegSHO reports that a security has been "shorted", as having a short position, or if it is just a type of reporting requirement for market making activities. It is both. Transactions that have shares marked as "short" can very well be an investor selling a short position or a market maker allocating shares in order to provide liquidity but not in their possession. The Division of Market Regulations of the SEC has an exhaustive, yet technical, overview of what RegSHO provides. Further information can be found at Key Points About Regulation SHO
2. Daily REGSHO Volumes
2.1 Short Volume
This is the combined number of shares traded and marked as "short" or "short exempt" for the specified security from all reporting TRF's.
2.2 TRF Total
This is the combined total number of shares traded on all TRF's for the specified security which include trades marked as "long".
2.3 Exempt Short
This is the combined total number of shares traded and marked as "short exempt" for the specified security from all reporting TRF's.
2.4 Total
This is the total number of shares traded for the specified security from all reporting facilities combined. This is most commonly known as total volume and includes share volume traded from other reporting facilities such as private brokerages, trading firms, etc. as well as the 3 main FINRA TRF's.
2.5 Adjusted
This is the total volume of shares marked "short" minus the total number of shares marked "short exempt".
This definition only applies to the data published on this website and is not provided by RegSHO. The data published on this websites combines and aggregates data from all 3 reports as well as perform computations on numbers in those reports.
3. Additional Daily Data
This data is daily and historical information provided alongside RegSHO information for the specified security. This information is not published or reported by FINRA RegSHO. This data is aggregated and compiled from public sources and many times is estimated when the data is not available.
3.1 Date
The trade date of which the corresponding data took place.
3.2 Hi/Lo
The highest and lowest price per share during regular trading hours for the specified security.
3.3 Total Dollar Volume
The total dollar amount traded for the specified security. * This is often estimated by averaging between a securities daily Hi and Lo multiplied by the amount of shares traded.
3.4 Number of Trades
The total number of trades executed for the specified security.
3.5 Trading Status
The current or end of day trading status for the specified security reported as "R" for regular/normal or "S" for suspended/halted.
3.6 CUSIP
A unique indentifying number for all stocks and bonds assigned by the Committee on Uniform Securities Identification Procedures (CUSIP).
Die aktienkultur geht in Richtung PC
Ein sehr hoher Anteil der Anleger halten ihre Aktien zwischen
0;23-0,330 Minuten
Das heißt im Klartext das Geld wird in Minuten verdient
Der Kurs spielt keine Rolle
Und der Kleinanleger bleibt auf der Strecke.
Scheinst ja sehr aktiv im Chat zu sein dort, wenn du weist was er so "sagt".. :D
Mal sehen, was an Volumen bis 15Uhr30 reinkommt
http://www.nasdaq.com/symbol/aezs/premarket
Und dann umso heftiger.
Ich habe meine Shares und warte (wie lange, kann ich sowieso nicht beeinflussen).
Das meine Warterei irgendwann belohnt wird, davon bin ich überzeugt.
Das sind jetzt keine Durchhalteparolen, sondern meine feste Überzeugung.
ich habe heute bei 0,478 noch mal nachgelegt.
Spätestens in Januar geht es los.
Die müssen die Aktie irgendwann ja auch über 1 USD bringen (kann mir nicht vorstellen, das ein Abstieg aus dem NASDAQ im Interesse derer liegt, welche den Kurs zur Zeit deckeln).
Ist aber nur meine Meinung
https://www.americanbulls.com/SignalPage.aspx?lang=de&Ticker=AEZS
Hoffentlich galoppelt das weisse Ross mit großer Ausdauer ;)
http://www.nasdaq.com/press-release/...nimum-bid-price-20141219-00352
Die kommen so schnell wie deine 50 cent bei Paion.
Das wird langsam langweilig, versuch doch mal eine etwas logischere Variante des bashen.
Oder schreib wenigsten, womit Du 22 cent bis "event." Mitte Januar begründest (zumal AEZS jetzt erst mal 180 Tage Zeit hat um den Dollar zu schaffen)